{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:51:03Z","timestamp":1774957863278,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fluoroquinolones (FQs) are known to be accompanied by significant risks. However, the incidence of adverse events (ADEs) resulting in unplanned drug discontinuation when used for periprosthetic joint infections (PJIs) is currently unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study included 156 patients over the age of 18 treated for staphylococcal PJI with debridement, antibiotics, and implant retention between 1 January 2007 and 21 November 2019. Of the 156 patients, 64 had total hip arthroplasty (THA) and 92 had total knee arthroplasty (TKA) infections. The primary outcome was rate of unplanned drug discontinuation. Secondary outcomes included incidence of severe ADEs, unplanned rifamycin discontinuation, mean time to unplanned regimen discontinuation, and all-cause mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, unplanned drug discontinuation occurred in 35.6% of patients in the FQ group and 3% of patients in the non-FQ group. The rate of unplanned discontinuation of FQ regimens as compared with non-FQ regimens was 27.5% vs 4.2% (P\u2005=\u2005.021) in THA infections and 42% vs 2.4% (P\u2005&amp;lt;\u2005.001) in TKA infections. There was no significant difference in severe ADEs between FQ and non-FQ regimens in both THA and TKA infections. The overall rate of nonsevere ADEs in FQ compared with non-FQ regimens was 43.3% vs 6.1% (P\u2005&amp;lt;\u2005.001). FQs were associated with tendinopathy, myalgia, arthralgia, and nausea.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A significantly higher rate of unplanned drug discontinuation was associated with FQ as compared with non-FQ regimens. This provides a real-world view of the implications of FQ-related ADEs on unplanned discontinuation when used in prolonged durations for the management of staphylococcal PJIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab145","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T12:43:13Z","timestamp":1613220193000},"page":"850-856","source":"Crossref","is-referenced-by-count":34,"title":["Safety and Tolerability of Fluoroquinolones in Patients with Staphylococcal Periprosthetic Joint Infections"],"prefix":"10.1093","volume":"73","author":[{"given":"Nicholas J","family":"Vollmer","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina G","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan W","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin P","family":"Oravec","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin C","family":"Mara","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina A","family":"Suh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas R","family":"Osmon","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena N","family":"Beam","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P","family":"Abdel","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abinash","family":"Virk","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic Hospital, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"2021090720314509400_CIT0001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2021090720314509400_CIT0002","author":"US Food and Drug Administration","year":"2018"},{"key":"2021090720314509400_CIT0003","doi-asserted-by":"crossref","first-page":"1228, e23","DOI":"10.1016\/j.amjmed.2012.05.027","article-title":"Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders","volume":"125","author":"Wise","year":"2012","journal-title":"Am J Med"},{"key":"2021090720314509400_CIT0004","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021090720314509400_CIT0005","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.0000000000000846","article-title":"Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study","volume":"83","author":"Etminan","year":"2014","journal-title":"Neurology"},{"key":"2021090720314509400_CIT0006","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1098-3597(03)90027-5","article-title":"Safety and tolerability of fluoroquinolones","volume":"5","author":"Sprandel","year":"2003","journal-title":"Clin Cornerstone"},{"key":"2021090720314509400_CIT0007","doi-asserted-by":"crossref","first-page":"k678","DOI":"10.1136\/bmj.k678","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study","volume":"360","author":"Pasternak","year":"2018","journal-title":"BMJ"},{"key":"2021090720314509400_CIT0008","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijantimicag.2018.04.014","article-title":"Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Tandan","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021090720314509400_CIT0009","doi-asserted-by":"crossref","first-page":"e00438-18","DOI":"10.1128\/AAC.00438-18","article-title":"Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides","volume":"62","author":"Gorelik","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021090720314509400_CIT0010","doi-asserted-by":"crossref","first-page":"ofx171","DOI":"10.1093\/ofid\/ofx171","article-title":"Risk factors for community-associated Clostridium difficile infection in adults: a case-control study","volume":"4","author":"Guh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021090720314509400_CIT0011","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1503\/cmaj.111823","article-title":"Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study","volume":"184","author":"Paterson","year":"2012","journal-title":"CMAJ"},{"key":"2021090720314509400_CIT0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.4199","article-title":"Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection","author":"Gopalakrishnan","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2021090720314509400_CIT0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.4192","article-title":"Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection","author":"Dong","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2021090720314509400_CIT0014","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/cid\/ciz261","article-title":"Benefits and adverse events associated with extended antibiotic use in total knee arthroplasty periprosthetic joint infection","volume":"70","author":"Shah","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021090720314509400_CIT0015","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant\u2013related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"2021090720314509400_CIT0016","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1179\/joc.2007.19.6.688","article-title":"Safety of prolonged high-dose levofloxacin therapy for bone infections","volume":"19","author":"Senneville","year":"2007","journal-title":"J Chemother"},{"key":"2021090720314509400_CIT0017","first-page":"61","article-title":"Maintaining a hip registry for 25 years: Mayo Clinic experience","volume-title":"Clinical orthopaedics and related research","author":"Berry","year":"1997"},{"key":"2021090720314509400_CIT0018","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2016.05.021","article-title":"Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial","volume":"48","author":"Lora-Tamayo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2021090720314509400_CIT0019","first-page":"135","article-title":"FDA adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics","volume":"337","author":"Tanne","year":"2008","journal-title":"BMJ"},{"key":"2021090720314509400_CIT0020","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/acr.22233","article-title":"Time trends in the characteristics of patients undergoing primary total knee arthroplasty","volume":"66","author":"Singh","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2021090720314509400_CIT0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jinf.2014.07.008","article-title":"Factors related to outcome of early and delayed prosthetic joint infections","volume":"70","author":"Ascione","year":"2015","journal-title":"J Infect"},{"key":"2021090720314509400_CIT0022","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/jac\/dkz122","article-title":"From \u201cOPAT\u201d to \u201cCOpAT\u201d: implications of the OVIVA study for ambulatory management of bone and joint infection","volume":"74","author":"Seaton","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021090720314509400_CIT0023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciz073","article-title":"Early infectious disease outpatient follow-up of outpatient parenteral antimicrobial therapy patients reduces 30-day readmission","volume":"69","author":"Saini","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab145\/37414309\/ciab145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/5\/850\/40326322\/ciab145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/5\/850\/40326322\/ciab145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T20:32:31Z","timestamp":1631046751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/5\/850\/6144987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,19]]},"published-print":{"date-parts":[[2021,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab145","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,2,19]]}}}